Gastroenterology
Volume 137, Issue 3 , Pages 914-923 , September 2009

Saccharomyces boulardii Inhibits EGF Receptor Signaling and Intestinal Tumor Growth in Apcmin Mice

  • Xinhua Chen

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Johannes Fruehauf

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Jeffrey D. Goldsmith

      Affiliations

    • Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Hua Xu

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Kianoosh K. Katchar

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Hon–Wai Koon

      Affiliations

    • Inflammatory Bowel Disease Center, Division of Digestive Diseases, UCLA, Los Angeles, California
    • ,
  • Dezheng Zhao

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Efi G. Kokkotou

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • ,
  • Charalabos Pothoulakis

      Affiliations

    • Inflammatory Bowel Disease Center, Division of Digestive Diseases, UCLA, Los Angeles, California
    • ,
  • Ciarán P. Kelly

      Affiliations

    • Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationReprint requests Address requests for reprints to: Ciarán P. Kelly, MD, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215

Received 8 February 2008 ,Accepted 14 May 2009.

References 

  1. Elmer GW, Surawicz CM, McFarland LV. Biotherapeutic agents (A neglected modality for the treatment and prevention of selected intestinal and vaginal infections). JAMA. 1996;275:870–876
  2. Sullivan A, Nord CE. The place of probiotics in human intestinal infections. Int J Antimicrob Agents. 2002;20:313–319
  3. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45:1462–1464
  4. Castagliuolo I, LaMont JT, Nikulasson ST, et al. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 1996;64:5225–5232
  5. Czerucka D, Dahan S, Mograbi B, et al. Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun. 2000;68:5998–6004
  6. Czerucka D, Roux I, Rampal P. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3′,5′-cyclic monophosphate induction in intestinal cells. Gastroenterology. 1994;106:65–72
  7. Dalmasso G, Cottrez F, Imbert V, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006;131:1812–1825
  8. Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun. 2003;71:766–773
  9. Chen X, Kokkotou EG, Mustafa N, et al. Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis. J Biol Chem. 2006;281:24449–24454
  10. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol. 2005;6:322–327
  11. Jimeno A, Hidalgo M. Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta. 2006;1766:217–229
  12. de Castro-Carpeno J, Belda-Iniesta C, Casado Saenz E, et al. EGFR and colon cancer: a clinical view. Clin Transl Oncol. 2008;10:6–13
  13. Calonghi N, Pagnotta E, Parolin C, et al. A new EGFR inhibitor induces apoptosis in colon cancer cells. Biochem Biophys Res Commun. 2007;354:409–413
  14. Ponz-Sarvise M, Rodriguez J, Viudez A, et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?. World J Gastroenterol. 2007;13:5877–5887
  15. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer. 2006;107:1207–1218
  16. Li Y, Sun X, LaMont JT, Pardee AB, et al. Selective killing of cancer cells by β-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci U S A. 2003;100:2674–2678
  17. Sougioultzis S, Simeonidis S, Bhaskar KR, et al. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-κB-mediated IL-8 gene expression. Biochem Biophys Res Commun. 2006;343:69–76
  18. Jiang D, Yang H, Willson JK, et al. Autocrine transforming growth factor α provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states. J Biol Chem. 1998;273:31471–31479
  19. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs. 1999;17:259–269
  20. Nautiyal J, Rishi AK, Majumdar AP. Emerging therapies in gastrointestinal cancers. World J Gastroenterol. 2006;12:7440–7450
  21. Roberts RB, Min L, Washington MK, et al. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci U S A. 2002;99:1521–1526
  22. Moran AE, Hunt DH, Javid SH, et al. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem. 2004;279:43261–43272
  23. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia. 2008;13:215–223
  24. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8:915–928
  25. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–137
  26. Le Roy C, Wrana JL. Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol. 2005;6:112–126
  27. Miljan EA, Bremer EG. Regulation of growth factor receptors by gangliosides. Sci STKE. 2002;2002:RE15
  28. Thiel KW, Carpenter G. ErbB-4 and TNF-α converting enzyme localization to membrane microdomains. Biochem Biophys Res Commun. 2006;350:629–633
  29. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microbes Infect. 2000;2:681–686
  30. Rafter J. Probiotics and colon cancer. Best Pract Res Clin Gastroenterol. 2003;17:849–859
  31. Brady LJ, Gallaher DD, Busta FF. The role of probiotic cultures in the prevention of colon cancer. J Nutr. 2000;130:S410–S414
  32. Chen X, Kelly C. Saccharomyces spp. In:  Versalovic J,  Wilson M editor. Therapeutic micriobiology: probiotics and related strategies. 1st ed.. Washington, DC: ASM Press; 2008;p. 51–60
  33. Pothoulakis C, Kelly CP, Joshi MA, et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993;104:1108–1115
  34. Gedek BR. Adherence of Escherichia coli serogroup O 157 and the Salmonella typhimurium mutant DT 104 to the surface of Saccharomyces boulardii. Mycoses. 1999;42:261–264
  35. Philpott DJ, McKay DM, Sherman PM, et al. Infection of T84 cells with enteropathogenic Escherichia coli alters barrier and transport functions. Am J Physiol. 1996;270:G634–G645
  36. Buts JP, Bernasconi P, Vaerman JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. 1990;35:251–256
  37. Qamar A, Aboudola S, Warny M, et al. Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice. Infect Immun. 2001;69:2762–2765
  38. Dalmasso G, Cottrez F, Imbert V, et al. Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology. 2006;131:1812–1825

 Conflicts of interest The authors disclose no conflicts.

 Funding Supported by NIH grants PO1 DK 33506 (to C.P.K.) and Crohn's and Colitis Foundation of America (research fellowship to X.C.).

PII: S0016-5085(09)00865-8

doi: 10.1053/j.gastro.2009.05.050

Gastroenterology
Volume 137, Issue 3 , Pages 914-923 , September 2009

Article Tools

* Image Usage & Resolution